Physician profile
Joel E Buchanan
NPI 1891777249
$2,545.74
in general payments reported to CMS, 2019-2025
27 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $325 · 2022: $194 · 2023: $445 · 2024: $464 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $509.83 | 2019-2025 | |
| Novo Nordisk INC | $373.10 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $209.13 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $181.13 | 2019-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $175.25 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $169.65 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $164.59 | 2023-2024 | Ubrelvy, Vraylar, Qulipta |
| Abbott Laboratories | $119.84 | 2023-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $117.38 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.83 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $57.71 | 2019-2020 | |
| Exact Sciences Corporation | $52.13 | 2023-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $35.62 | 2025 | Fluad, Flucelvax |
| Sanofi Pasteur INC. | $26.80 | 2019-2020 | |
| Genentech USA, INC. | $25.28 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.96 | 2019-2020 | |
| Boston Scientific Corporation | $23.73 | 2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.11 | 2024 | |
| Esperion Therapeutics, INC. | $21.08 | 2024 | Nexletol |
| Ibsa Pharma INC. | $20.66 | 2025 | Licart, Tirosint, Flector |
| Sunovion Pharmaceuticals INC. | $20.40 | 2019 | |
| Pacira Therapeutics, INC. | $18.75 | 2019 | |
| Astellas Pharma US INC | $17.55 | 2023 | Veozah |
| Currax Pharmaceuticals LLC | $14.10 | 2020 | |
| Gilead Sciences, INC. | $13.79 | 2019 | |
| Allergan, INC. | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.